Roche to present new obesity data at ADA 2026 Scientific Sessions
Late-stage data highlight efficacy and safety of investigational therapies enicepatide and petrelintide for weight management
5 Jun 2026Industry news
Roche will present new Phase II data from its obesity portfolio, including the investigational medicines enicepatide (CT-388) and petrelintide, at the American Diabetes Association® (ADA) 2026 Scientific Sessions in the United States.
The late-breaking results will highlight who may benefit from these therapies, adults living with overweight or obesity, including those with type 2 diabetes (T2D), what the data show on efficacy, safety, and tolerability, when and where the findings will be presented during the ADA meeting, and why they are important for advancing long-term weight management and treatment adherence.
Advancing obesity treatment with enicepatide and petrelintide
Roche’s new data from its obesity pipeline demonstrate meaningful progress in addressing unmet needs in obesity and overweight, including the need for long-term treatment adherence supported by favorable safety and tolerability.
“The data we will present at ADA highlight the growing strength of our obesity portfolio, exemplified by the robust efficacy and distinct tolerability profiles of enicepatide and petrelintide,” said Dr. Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development. “The clinical insights from these studies demonstrate how our portfolio may offer more tailored, individualised treatment options for people living with obesity.”
Enicepatide (CT-388): Dual GLP-1/GIP receptor agonist in Phase II
Late-breaking data from the Phase II CT388-103 study will present clinical weight loss outcomes with investigational enicepatide in people living with overweight or obesity. Enicepatide is a dual GLP-1/GIP receptor agonist designed to support significant weight loss.
An additional Phase II study, CT388-104, is evaluating the efficacy, safety, and tolerability of enicepatide in participants who are living with obesity or are overweight and have T2D. These data suggest that enicepatide could emerge as an important medicine in its own right and also serve as a key backbone for potential combination therapies within Roche’s cardiometabolic pipeline.
Petrelintide: Human amylin analog for weight management
Late-breaking data from the Phase II ZUPREME-1 trial will highlight the efficacy and safety of petrelintide, an investigational human amylin analog being evaluated for weight management in people living with overweight and obesity. The data include a compelling tolerability profile that has the potential to redefine the weight management experience.
The ongoing Phase II petrelintide monotherapy trial, ZUPREME-2, is evaluating petrelintide versus placebo in people living with obesity or overweight and T2D. As both monotherapy and in combination with enicepatide, petrelintide has the potential to become an important component of Roche’s obesity portfolio.
Future development plans and combination strategy
Roche continues to advance its weight management pipeline rapidly. The company is moving both enicepatide and petrelintide into Phase III development and plans to initiate a Phase II multi-arm trial in mid-2026 to evaluate fixed-dose combinations of enicepatide and petrelintide. This combination strategy aims to develop a differentiated treatment option for people living with overweight or obesity, including those with T2D.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
What Phase II obesity data will Roche present on enicepatide (CT-388) and petrelintide at the ADA 2026 Scientific Sessions in the United States?
Roche will present late-breaking Phase II data from its obesity portfolio at the American Diabetes Association (ADA) 2026 Scientific Sessions in the United States, focusing on the investigational medicines enicepatide (CT-388) and petrelintide.
For enicepatide, the Phase II CT388-103 study will report clinical weight loss outcomes in adults living with overweight or obesity, while the CT388-104 study is evaluating efficacy, safety, and tolerability in people with obesity or overweight and type 2 diabetes (T2D).
For petrelintide, the Phase II ZUPREME-1 trial will highlight efficacy and safety data in people with overweight and obesity, including a compelling tolerability profile. Together, these data are intended to show who may benefit from these therapies, how they perform on efficacy, safety, and tolerability, and why they are important for advancing long-term weight management and treatment adherence.
How do enicepatide (CT-388) and petrelintide fit into Roche’s long-term obesity and type 2 diabetes treatment strategy?
Enicepatide (CT-388) is a dual GLP-1/GIP receptor agonist in Phase II development, designed to support significant weight loss in adults living with overweight or obesity, including those with type 2 diabetes. Data from the CT388-103 and CT388-104 studies suggest that enicepatide could become an important standalone medicine and a key backbone for potential combination therapies within Roche’s cardiometabolic pipeline.
Petrelintide is an investigational long-acting human amylin analog being evaluated for weight management in people with overweight and obesity, including those with T2D in the ZUPREME-2 monotherapy trial. Roche plans to move both enicepatide and petrelintide into Phase III development and to initiate a Phase II multi-arm trial in mid-2026 to study fixed-dose combinations of the two agents, aiming to deliver differentiated, tailored treatment options that support long-term weight management and treatment adherence.